ECSP13012524A - Teobromina en combinación con un expectorante o un mucolítico para su uso en terapia - Google Patents
Teobromina en combinación con un expectorante o un mucolítico para su uso en terapiaInfo
- Publication number
- ECSP13012524A ECSP13012524A ECSP13012524A ECSP13012524A EC SP13012524 A ECSP13012524 A EC SP13012524A EC SP13012524 A ECSP13012524 A EC SP13012524A EC SP13012524 A ECSP13012524 A EC SP13012524A
- Authority
- EC
- Ecuador
- Prior art keywords
- theobromine
- expectorant
- mucolytic
- agent
- cough
- Prior art date
Links
- YAPQBXQYLJRXSA-UHFFFAOYSA-N theobromine Chemical compound CN1C(=O)NC(=O)C2=C1N=CN2C YAPQBXQYLJRXSA-UHFFFAOYSA-N 0.000 title abstract 18
- 239000003172 expectorant agent Substances 0.000 title abstract 10
- 229960004559 theobromine Drugs 0.000 title abstract 9
- 230000003419 expectorant effect Effects 0.000 title abstract 8
- 238000002560 therapeutic procedure Methods 0.000 title abstract 2
- 230000000510 mucolytic effect Effects 0.000 abstract 7
- 239000003795 chemical substances by application Substances 0.000 abstract 5
- 229940079593 drug Drugs 0.000 abstract 4
- 239000003814 drug Substances 0.000 abstract 4
- 230000000694 effects Effects 0.000 abstract 4
- 206010011224 Cough Diseases 0.000 abstract 3
- KRKNYBCHXYNGOX-UHFFFAOYSA-N citric acid Chemical compound OC(=O)CC(O)(C(O)=O)CC(O)=O KRKNYBCHXYNGOX-UHFFFAOYSA-N 0.000 abstract 3
- 229940066493 expectorants Drugs 0.000 abstract 2
- 229940066491 mucolytics Drugs 0.000 abstract 2
- HSRJKNPTNIJEKV-UHFFFAOYSA-N Guaifenesin Chemical compound COC1=CC=CC=C1OCC(O)CO HSRJKNPTNIJEKV-UHFFFAOYSA-N 0.000 abstract 1
- 229960002146 guaifenesin Drugs 0.000 abstract 1
- 230000001976 improved effect Effects 0.000 abstract 1
- 230000003389 potentiating effect Effects 0.000 abstract 1
- 230000002195 synergetic effect Effects 0.000 abstract 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/74—Synthetic polymeric materials
- A61K31/765—Polymers containing oxygen
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/045—Hydroxy compounds, e.g. alcohols; Salts thereof, e.g. alcoholates
- A61K31/047—Hydroxy compounds, e.g. alcohols; Salts thereof, e.g. alcoholates having two or more hydroxy groups, e.g. sorbitol
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/075—Ethers or acetals
- A61K31/085—Ethers or acetals having an ether linkage to aromatic ring nuclear carbon
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/075—Ethers or acetals
- A61K31/085—Ethers or acetals having an ether linkage to aromatic ring nuclear carbon
- A61K31/09—Ethers or acetals having an ether linkage to aromatic ring nuclear carbon having two or more such linkages
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/12—Ketones
- A61K31/122—Ketones having the oxygen directly attached to a ring, e.g. quinones, vitamin K1, anthralin
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/13—Amines
- A61K31/135—Amines having aromatic rings, e.g. ketamine, nortriptyline
- A61K31/137—Arylalkylamines, e.g. amphetamine, epinephrine, salbutamol, ephedrine or methadone
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/185—Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/185—Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
- A61K31/19—Carboxylic acids, e.g. valproic acid
- A61K31/195—Carboxylic acids, e.g. valproic acid having an amino group
- A61K31/197—Carboxylic acids, e.g. valproic acid having an amino group the amino and the carboxyl groups being attached to the same acyclic carbon chain, e.g. gamma-aminobutyric acid [GABA], beta-alanine, epsilon-aminocaproic acid or pantothenic acid
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/185—Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
- A61K31/19—Carboxylic acids, e.g. valproic acid
- A61K31/195—Carboxylic acids, e.g. valproic acid having an amino group
- A61K31/197—Carboxylic acids, e.g. valproic acid having an amino group the amino and the carboxyl groups being attached to the same acyclic carbon chain, e.g. gamma-aminobutyric acid [GABA], beta-alanine, epsilon-aminocaproic acid or pantothenic acid
- A61K31/198—Alpha-amino acids, e.g. alanine or edetic acid [EDTA]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/21—Esters, e.g. nitroglycerine, selenocyanates
- A61K31/215—Esters, e.g. nitroglycerine, selenocyanates of carboxylic acids
- A61K31/22—Esters, e.g. nitroglycerine, selenocyanates of carboxylic acids of acyclic acids, e.g. pravastatin
- A61K31/223—Esters, e.g. nitroglycerine, selenocyanates of carboxylic acids of acyclic acids, e.g. pravastatin of alpha-aminoacids
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/21—Esters, e.g. nitroglycerine, selenocyanates
- A61K31/215—Esters, e.g. nitroglycerine, selenocyanates of carboxylic acids
- A61K31/235—Esters, e.g. nitroglycerine, selenocyanates of carboxylic acids having an aromatic ring attached to a carboxyl group
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/21—Esters, e.g. nitroglycerine, selenocyanates
- A61K31/265—Esters, e.g. nitroglycerine, selenocyanates of carbonic, thiocarbonic, or thiocarboxylic acids, e.g. thioacetic acid, xanthogenic acid, trithiocarbonic acid
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/335—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin
- A61K31/357—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having two or more oxygen atoms in the same ring, e.g. crown ethers, guanadrel
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/38—Heterocyclic compounds having sulfur as a ring hetero atom
- A61K31/381—Heterocyclic compounds having sulfur as a ring hetero atom having five-membered rings
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
- A61K31/425—Thiazoles
- A61K31/426—1,3-Thiazoles
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/496—Non-condensed piperazines containing further heterocyclic rings, e.g. rifampin, thiothixene or sparfloxacin
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
- A61K31/519—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with heterocyclic rings
- A61K31/52—Purines, e.g. adenine
- A61K31/522—Purines, e.g. adenine having oxo groups directly attached to the heterocyclic ring, e.g. hypoxanthine, guanine, acyclovir
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/66—Phosphorus compounds
- A61K31/661—Phosphorus acids or esters thereof not having P—C bonds, e.g. fosfosal, dichlorvos, malathion or mevinphos
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K33/00—Medicinal preparations containing inorganic active ingredients
- A61K33/02—Ammonia; Compounds thereof
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K33/00—Medicinal preparations containing inorganic active ingredients
- A61K33/14—Alkali metal chlorides; Alkaline earth metal chlorides
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K33/00—Medicinal preparations containing inorganic active ingredients
- A61K33/18—Iodine; Compounds thereof
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
- A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- A61K38/43—Enzymes; Proenzymes; Derivatives thereof
- A61K38/46—Hydrolases (3)
- A61K38/47—Hydrolases (3) acting on glycosyl compounds (3.2), e.g. cellulases, lactases
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
- A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
- A61K9/16—Agglomerates; Granulates; Microbeadlets ; Microspheres; Pellets; Solid products obtained by spray drying, spray freeze drying, spray congealing,(multiple) emulsion solvent evaporation or extraction
- A61K9/1605—Excipients; Inactive ingredients
- A61K9/1617—Organic compounds, e.g. phospholipids, fats
- A61K9/1623—Sugars or sugar alcohols, e.g. lactose; Derivatives thereof; Homeopathic globules
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
- A61K9/16—Agglomerates; Granulates; Microbeadlets ; Microspheres; Pellets; Solid products obtained by spray drying, spray freeze drying, spray congealing,(multiple) emulsion solvent evaporation or extraction
- A61K9/1605—Excipients; Inactive ingredients
- A61K9/1629—Organic macromolecular compounds
- A61K9/1658—Proteins, e.g. albumin, gelatin
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
- A61P11/10—Expectorants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
- A61P11/12—Mucolytics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
- A61P11/14—Antitussive agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- General Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Veterinary Medicine (AREA)
- Medicinal Chemistry (AREA)
- Public Health (AREA)
- Pharmacology & Pharmacy (AREA)
- Animal Behavior & Ethology (AREA)
- Epidemiology (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Engineering & Computer Science (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Organic Chemistry (AREA)
- General Chemical & Material Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Emergency Medicine (AREA)
- Pulmonology (AREA)
- Inorganic Chemistry (AREA)
- Gastroenterology & Hepatology (AREA)
- Molecular Biology (AREA)
- Biophysics (AREA)
- Immunology (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Medicinal Preparation (AREA)
- Saccharide Compounds (AREA)
Abstract
Un agente comprende teobromina y un expectorante, o un agente comprende teobromina y un mucolítico. El agente de la invención se puede usar como una preparación combinada para el uso simultáneo, consecutivo o por separado en la terapia de la tos. Dado que un mucolítico o un expectorante es potencialmente protusivo, fue sorprendente descubrir que un mucolítico/expectorante y la teobromina tuvieron sinergia. Basado en lo que se sabe acerca de los expectorantes/mucolíticos, se esperaba que un expectorante/mucolítico reduciría la eficacia de la teobromina. La invención en consecuencia está basada al menos parcialmente en los datos que muestran efectos antitusivos sinergísticos para la teobromina combinada con guaifenesina en un modelo de tos inducida por ácido cítrico. Cuando los expectorantes y/o mucolíticos se combinan con la teobromina, los efectos son sorpresivamente potentes y mayores que la suma los fármacos individuales, lo cual revela que la combinación tiene un efecto sustancialmente mejorado. En consecuencia, una dosis considerablemente reducida de ambos fármacos se puede administrar para un efecto equivalente para cada fármaco individual, reduciendo entonces los efectos colaterales y la carga de fármaco. En consecuencia, la presente invención es un agente que comprende teobromina y un expectorante, o un agente que comprende teobromina y un mucolítico.
Applications Claiming Priority (2)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
GBGB1014391.5A GB201014391D0 (en) | 2010-08-27 | 2010-08-27 | Drug composition and its use in therapy |
PCT/GB2011/051610 WO2012025761A1 (en) | 2010-08-27 | 2011-08-25 | Theobromine in combination with an expectorant or a mucolytic for use in therapy |
Publications (1)
Publication Number | Publication Date |
---|---|
ECSP13012524A true ECSP13012524A (es) | 2013-05-31 |
Family
ID=43013412
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
ECSP13012524 ECSP13012524A (es) | 2010-08-27 | 2013-03-25 | Teobromina en combinación con un expectorante o un mucolítico para su uso en terapia |
Country Status (19)
Country | Link |
---|---|
EP (1) | EP2608847B1 (es) |
JP (2) | JP2013536257A (es) |
CN (1) | CN103189108B (es) |
AU (1) | AU2011294905B2 (es) |
BR (1) | BR112013004659A8 (es) |
CA (1) | CA2809767A1 (es) |
CO (1) | CO6700840A2 (es) |
EA (1) | EA201390287A1 (es) |
EC (1) | ECSP13012524A (es) |
ES (1) | ES2672128T3 (es) |
GB (1) | GB201014391D0 (es) |
IL (1) | IL224953A (es) |
MX (1) | MX343598B (es) |
NZ (1) | NZ607670A (es) |
PE (1) | PE20140013A1 (es) |
PL (1) | PL2608847T3 (es) |
SG (1) | SG188322A1 (es) |
UA (1) | UA112760C2 (es) |
WO (1) | WO2012025761A1 (es) |
Families Citing this family (7)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
GB0910375D0 (en) | 2009-06-16 | 2009-07-29 | Biocopea Ltd | Drug composition and its use in therapy |
GB201111485D0 (en) * | 2011-07-05 | 2011-08-17 | Biocopea Ltd | Drug composition and its use in therapy |
US9308211B2 (en) | 2009-06-16 | 2016-04-12 | Infirst Healthcare Limited | Drug combinations and uses in treating a coughing condition |
US10016437B2 (en) | 2009-06-16 | 2018-07-10 | Infirst Healthcare Limited | Drug combinations and uses in treating a coughing condition |
US9314465B2 (en) | 2009-06-16 | 2016-04-19 | Infirst Healthcare Limited | Drug combinations and uses in treating a coughing condition |
MX2017002948A (es) * | 2014-09-08 | 2017-08-15 | Gotham Biopharmaceuticals Inc | Métodos de tratamiento para la sarcoidosis pulmonar. |
CN108601755B (zh) * | 2015-09-09 | 2021-08-10 | 韩国生命工学研究院 | 用于预防或治疗肌无力相关疾病的、包含水合蒎醇的组合物 |
Family Cites Families (14)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
HUP9700654A2 (hu) | 1997-03-26 | 1999-09-28 | Dezső Korbonits | Teobromin tartalmú köhögéscsillapító készítmények |
AU4699299A (en) * | 1998-06-26 | 2000-01-17 | Nutracorp Scientific, Inc. | Promoting nitric oxide and cyclic gmp activity |
JP2002193839A (ja) * | 2000-12-27 | 2002-07-10 | Meiji Seika Kaisha Ltd | ココア製剤 |
JP2003055258A (ja) * | 2001-08-16 | 2003-02-26 | Rohto Pharmaceut Co Ltd | 安定化された組成物 |
US7097859B2 (en) * | 2004-04-05 | 2006-08-29 | Hack Jacob C | Indium supplement compositions and methods therefor |
US20060148837A1 (en) * | 2005-01-04 | 2006-07-06 | Everett Laboratories, Inc. | Compositions and methods for treatment of coughing, sneezing, rhinorrhea, and/or nasal obstruction |
GB2424185B (en) * | 2005-03-16 | 2009-12-30 | Atulkumar Sumanbhai Patel | A cough mixture |
KR20080009994A (ko) * | 2006-07-25 | 2008-01-30 | 안국약품 주식회사 | 기침 치료용 조성물 |
US20080085312A1 (en) * | 2006-10-04 | 2008-04-10 | Auriga Laboratories, Inc. | Multi-Phase Release Potassium Guaiacolsulfonate Compositions |
US20080176955A1 (en) * | 2007-01-16 | 2008-07-24 | Victory Pharma, Inc. | Combined administration of benzonatate and guaifenesin |
DE102007000521A1 (de) * | 2007-10-18 | 2009-04-23 | Renate Conrad | Hustenpräparat |
GB201111485D0 (en) * | 2011-07-05 | 2011-08-17 | Biocopea Ltd | Drug composition and its use in therapy |
GB0910375D0 (en) * | 2009-06-16 | 2009-07-29 | Biocopea Ltd | Drug composition and its use in therapy |
EP2571499A1 (en) * | 2010-05-18 | 2013-03-27 | Mahmut Bilgic | Pharmaceutical composition comprising n- acetylcysteine and a xanthine |
-
2010
- 2010-08-27 GB GBGB1014391.5A patent/GB201014391D0/en not_active Ceased
-
2011
- 2011-08-25 CN CN201180052248.7A patent/CN103189108B/zh not_active Expired - Fee Related
- 2011-08-25 WO PCT/GB2011/051610 patent/WO2012025761A1/en active Application Filing
- 2011-08-25 BR BR112013004659A patent/BR112013004659A8/pt not_active IP Right Cessation
- 2011-08-25 SG SG2013014816A patent/SG188322A1/en unknown
- 2011-08-25 AU AU2011294905A patent/AU2011294905B2/en not_active Ceased
- 2011-08-25 UA UAA201303724A patent/UA112760C2/uk unknown
- 2011-08-25 ES ES11755105.1T patent/ES2672128T3/es active Active
- 2011-08-25 NZ NZ607670A patent/NZ607670A/en not_active IP Right Cessation
- 2011-08-25 EA EA201390287A patent/EA201390287A1/ru unknown
- 2011-08-25 EP EP11755105.1A patent/EP2608847B1/en active Active
- 2011-08-25 CA CA2809767A patent/CA2809767A1/en not_active Abandoned
- 2011-08-25 MX MX2013002334A patent/MX343598B/es active IP Right Grant
- 2011-08-25 PL PL11755105T patent/PL2608847T3/pl unknown
- 2011-08-25 PE PE2013000352A patent/PE20140013A1/es not_active Application Discontinuation
- 2011-08-25 JP JP2013526551A patent/JP2013536257A/ja active Pending
-
2013
- 2013-02-27 IL IL224953A patent/IL224953A/en not_active IP Right Cessation
- 2013-03-22 CO CO13057476A patent/CO6700840A2/es unknown
- 2013-03-25 EC ECSP13012524 patent/ECSP13012524A/es unknown
-
2016
- 2016-08-04 JP JP2016153321A patent/JP2016196504A/ja active Pending
Also Published As
Publication number | Publication date |
---|---|
PL2608847T3 (pl) | 2018-08-31 |
WO2012025761A1 (en) | 2012-03-01 |
EP2608847A1 (en) | 2013-07-03 |
AU2011294905A1 (en) | 2013-03-21 |
BR112013004659A2 (pt) | 2016-08-02 |
AU2011294905B2 (en) | 2015-01-15 |
BR112013004659A8 (pt) | 2018-01-02 |
CN103189108A (zh) | 2013-07-03 |
CA2809767A1 (en) | 2012-03-01 |
NZ607670A (en) | 2015-06-26 |
PE20140013A1 (es) | 2014-01-24 |
MX2013002334A (es) | 2013-03-18 |
ES2672128T3 (es) | 2018-06-12 |
JP2016196504A (ja) | 2016-11-24 |
EA201390287A1 (ru) | 2013-07-30 |
MX343598B (es) | 2016-11-11 |
CN103189108B (zh) | 2017-02-08 |
GB201014391D0 (en) | 2010-10-13 |
UA112760C2 (uk) | 2016-10-25 |
IL224953A (en) | 2016-03-31 |
SG188322A1 (en) | 2013-04-30 |
CO6700840A2 (es) | 2013-06-28 |
JP2013536257A (ja) | 2013-09-19 |
EP2608847B1 (en) | 2018-03-21 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
ECSP13012524A (es) | Teobromina en combinación con un expectorante o un mucolítico para su uso en terapia | |
CO2017001493A2 (es) | Kits que comprenden inhibidores tigit y agentes anticáncer | |
NI201700032A (es) | Uso de un agonista dual del receptor de glp-1/glucagón de acción prolongada para el tratamiento de la enfermedad del higado graso no alcohólico | |
BR112015027282A2 (pt) | fenfluramina para uso no tratamento de síndrome de dravet | |
AR092177A1 (es) | Metodos para tratar o prevenir asma administrando un antagonista de il-4r | |
BR112015023922A2 (pt) | composição farmacêutica compreendendo um ativador de ampk e um agente serotonérgico e métodos de uso destes | |
BR112013000537A2 (pt) | composição aquosa contendo bromexina | |
BR112016012506A8 (pt) | combinações farmacêuticas, seus usos, e uso de um portador de dados | |
BR112019005046A2 (pt) | combinações terapêuticas compreendendo um inibidor de raf e um inibidor de erk | |
AR096892A1 (es) | Una combinación farmacéutica para el tratamiento del melanoma | |
CU20150163A7 (es) | DERIVADOS DE 5-HETEROARIL-4-FENIL-4,5-DIHIDROPIRROLO(3,4-c)PIRAZOL-6-ONA ACTIVOS COMO INHIBIDORES DE BET | |
BR112016007946A2 (pt) | combinação farmacêutica, usos da mesma, de plinabulina e de composição, kits ou mistura e método para tratar e/ou prevenir câncer | |
BR112015026238A8 (pt) | composto dihidropirazino-pirazina, composição farmacêutica que o compreende, uso do composto, métodos para inibir ou medir a fosforilação e para inibir a atividade da proteína quinase, bem como kit | |
MX2014002171A (es) | Tratamientos de combinacion para hepatitis c. | |
CR11418A (es) | Trans-clomifeno para el sindrome metabolico | |
AR070026A1 (es) | Conjunto de elementos para la dosificacion de 1-amino-alquilciclohexanos, tal como neramexano, y tratamiento de diversas enfermedades incluyendo el tinnitus | |
CY1114163T1 (el) | Μεθοδοι χρησεως ανταγωνιστων αγγειοπιεσινης με παραγοντες χημειοθεραπειας ανθρακυκλινης για να μειωνεται καρδιοτοξικοτητα ή/και να βελτιωνεται επιβιωση | |
AR122352A1 (es) | Un esteroide c21-n-pirazolilo 19-nor c3,3 disustituido y métodos de uso de este | |
DOP2014000269A (es) | Nueva dosificación y formulación | |
CL2013003700A1 (es) | Composicion farmaceutica oftalmologica topica que comprende regorafenib, el cual se encuentra suspendido en un vehiculo farmaceuticamente aceptable; procedimiento de fabricacion y su uso para tratar o prevenir un trastorno oftalmologico. | |
BR112015029894A2 (pt) | forma de dosagem farmacêutica sólida | |
CO6361950A2 (es) | Composiciones, vacunas y metodos del virus del herpes del ganado bovino -1 | |
CO2018004665A2 (es) | Compuestos oxadiazoespíricos | |
AR102778A1 (es) | Composición farmacéutica, su preparación y sus usos | |
UY35890A (es) | Uso de laquinimod para retrasar la progresión de la enfermedad de huntington |